Dynamic Technology Lab Private Ltd Purchases New Shares in COMPASS Pathways plc (NASDAQ:CMPS)

Dynamic Technology Lab Private Ltd acquired a new position in shares of COMPASS Pathways plc (NASDAQ:CMPS) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 21,945 shares of the company’s stock, valued at approximately $83,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CMPS. Conservest Capital Advisors Inc. increased its stake in shares of COMPASS Pathways by 28.9% during the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after purchasing an additional 3,000 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in COMPASS Pathways during the 4th quarter worth approximately $41,000. Wealthfront Advisers LLC purchased a new stake in COMPASS Pathways during the 4th quarter worth approximately $43,000. Flagship Harbor Advisors LLC acquired a new position in shares of COMPASS Pathways during the fourth quarter valued at approximately $43,000. Finally, Franklin Resources Inc. lifted its position in shares of COMPASS Pathways by 4.4% in the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock valued at $1,810,000 after acquiring an additional 12,599 shares in the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Trading Up 5.6 %

Shares of CMPS stock opened at $2.85 on Friday. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways plc has a twelve month low of $2.49 and a twelve month high of $9.63. The company’s 50-day moving average price is $3.57 and its 200-day moving average price is $4.38. The stock has a market cap of $264.12 million, a price-to-earnings ratio of -1.30 and a beta of 2.34.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, equities analysts predict that COMPASS Pathways plc will post -2.33 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on CMPS. Canaccord Genuity Group reduced their price objective on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, February 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research report on Friday, March 28th. Stifel Nicolaus started coverage on shares of COMPASS Pathways in a research report on Thursday, February 27th. They set a “buy” rating and a $11.00 price target on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $20.20.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.